AX-2026-041600 · CJC-1295 (no DAC) · QSC lot QSC-2606-V7416

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 35 min gradient, 214 nm	97.74	% area	≥ 98.0	FAIL
Total impurities	RP-HPLC, sum of reported peaks	2.26	% area	≤ 2.0	FAIL
Largest single impurity	RP-HPLC — des-Tyr1 (−163 Da)	0.84	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Total peptide content	by difference from the gravimetric mass balance	90.90	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	88.85	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	2.27	mg	2 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	2.017	mg	2 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	100.9	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	4.91	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	3.46	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.73	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White cake, partially collapsed	—	white to off-white intact cake	FAIL
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.92	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 35 min gradient	14.84	min	14.83 ± 0.30 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.11	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	51,404	—	≥ 20,000	PASS
Resolution to nearest impurity	vs deamidated (+1 Da)	1.04	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 35 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 51,404, and skew follows the reported asymmetry factor of 1.11. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.84 % impurity against a 97.74 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	CJC-1295 (no DAC) — main peak	14.84	4,750,467	97.74	—
2	des-Tyr1 (−163 Da)	14.21	40,827	0.84	-163.063
3	native GRF (1-29) (−59 Da)	14.44	32,564	0.67	-58.995
4	truncated (1-24)	13.49	22,357	0.46	-570.291
5	acetyl adduct (+42 Da)	15.35	7,290	0.15	+42.011
6	deamidated (+1 Da)	14.56	6,804	0.14	+0.984
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	4.91
Counter-ion (acetate)	ion chromatography	3.46
Residual solvent + inorganic residue	estimated	0.73
Total peptide content	by difference	90.90
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	97.60	97.74	divergence -0.43 pp vs batch median
Total impurities (% area)	not stated	2.26
Largest single impurity (% area)	not stated	0.84
Water (%)	not stated	4.91
Counter-ion (%)	not stated	3.46
Peptide content (%w/w)	not stated	90.90
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → third-party forwarder (29 d) → laboratory (courier, cold pack, 3 d) → assay.
Assay date: 26 Aug 2026
Submitted to the index: 03 Sep 2026
Laboratory: Nordanalyt Laboratories, Uppsala, Sweden
Method basis: 35 min gradient · high-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

mass_defect03 Sep 2026

Before assigning des-Tyr1 (−163 Da) from retention alone, check the mass defect on the impurity peak. Plausible and implausible assignments separate cleanly and the check costs nothing.

aaa_hydrolysis03 Sep 2026

Content by hydrolysis assumes complete recovery of every residue. Where it disagrees with the balance by a percent or two, the hydrolysis is the more likely culprit.

schema_v203 Sep 2026

All four balance components are separate fields in the published dataset, so the closure can be re-derived from the CSV rather than taken on trust. That is the intent.

Section 7

Related records

Same batch — lot QSC-2606-V7416 n=9

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041598	QSC-2606-V7416	Janoshik	2026-Q3	98.16	3.76	—	Buyer-sourced	1	MARGINAL
AX-2026-041599	QSC-2606-V7416	VendorInvestigate	2026-Q3	97.96	3.52	—	Buyer-sourced	1	FAIL
AX-2026-041601	QSC-2606-V7416	Kestrel	2026-Q3	98.33	4.10	—	Buyer-sourced	1	MARGINAL
AX-2026-041602	QSC-2606-V7416	VendorInvestigate	2026-Q3	98.36	3.38	101.8	Buyer-sourced	1	MARGINAL
AX-2026-041603	QSC-2606-V7416	PeptideMeter	2026-Q3	98.43	4.20	—	Buyer-sourced	1	MARGINAL
AX-2026-041604	QSC-2606-V7416	VendorInvestigate	2026-Q3	97.89	3.60	95.0	Buyer-sourced	1	FAIL
AX-2026-041605	QSC-2606-V7416	PeptideMeter	2026-Q3	97.96	3.59	102.5	Laboratory-retained	1	FAIL
AX-2026-041606	QSC-2606-V7416	Janoshik	2026-Q3	98.03	3.58	—	Buyer-sourced	1	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent CJC-1295 (no DAC) records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042942	MKM	MKM-2603-V3346	Janoshik	2026-Q3	99.52	3.43	—	Supplier-supplied	0	PASS
AX-2026-041599	QSC	QSC-2606-V7416	VendorInvestigate	2026-Q3	97.96	3.52	—	Buyer-sourced	1	FAIL
AX-2026-042784	GGPeps	GGPE-2606-E1234	Medutest	2026-Q3	98.27	4.55	—	Buyer-sourced	0	PASS
AX-2026-042939	MKM	MKM-2603-V3346	PeptideMeter	2026-Q3	99.44	3.39	—	Buyer-sourced	0	PASS
AX-2026-041601	QSC	QSC-2606-V7416	Kestrel	2026-Q3	98.33	4.10	—	Buyer-sourced	1	MARGINAL
AX-2026-042945	MKM	MKM-2603-V3346	PeptideMeter	2026-Q3	99.39	3.54	—	Laboratory-retained	0	PASS
AX-2026-042786	GGPeps	GGPE-2606-E1234	Janoshik	2026-Q3	98.22	3.77	—	Buyer-sourced	0	PASS
AX-2026-041602	QSC	QSC-2606-V7416	VendorInvestigate	2026-Q3	98.36	3.38	101.8	Buyer-sourced	1	MARGINAL

Other recent QSC records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041599	CJC-1295 (no DAC)	QSC-2606-V7416	VendorInvestigate	2026-Q3	97.96	3.52	—	Buyer-sourced	1	FAIL
AX-2026-041601	CJC-1295 (no DAC)	QSC-2606-V7416	Kestrel	2026-Q3	98.33	4.10	—	Buyer-sourced	1	MARGINAL
AX-2026-041602	CJC-1295 (no DAC)	QSC-2606-V7416	VendorInvestigate	2026-Q3	98.36	3.38	101.8	Buyer-sourced	1	MARGINAL
AX-2026-041477	Triptorelin	QSC-2607-C5749	Nordanalyt	2026-Q3	99.53	3.42	—	Buyer-sourced	0	PASS
AX-2026-041603	CJC-1295 (no DAC)	QSC-2606-V7416	PeptideMeter	2026-Q3	98.43	4.20	—	Buyer-sourced	1	MARGINAL
AX-2026-041606	CJC-1295 (no DAC)	QSC-2606-V7416	Janoshik	2026-Q3	98.03	3.58	—	Buyer-sourced	1	MARGINAL
AX-2026-041585	Liraglutide	QSC-2605-W7381	Medutest	2026-Q3	99.59	5.09	92.8	Laboratory-retained	0	PASS
AX-2026-041586	Liraglutide	QSC-2605-W7381	Janoshik	2026-Q3	98.85	6.00	90.7	Buyer-sourced	0	PASS